Cell-type-directed network-correcting combination therapy for Alzheimer's disease.

Area of Science:

• Neuroscience
• Genomics
• Pharmacology

Background:

• Alzheimer's disease (AD) is a complex neurodegenerative disorder with diverse cellular changes, complicating treatment.
• Current therapeutic strategies face challenges due to the multifactorial nature of AD.

Purpose of the Study:

• To develop a cell-type-specific, multi-target drug discovery strategy for Alzheimer's disease.
• To identify and evaluate a novel combination therapy for AD using human data and real-world evidence.

Main Methods:

• Integration of single-cell transcriptomics, drug perturbation databases, and clinical records.
• Identification of letrozole and irinotecan as a potential combination therapy.
• Evaluation of the combination therapy in an AD mouse model with Aβ and tau pathology.

Main Results:

• The letrozole and irinotecan combination therapy significantly improved memory performance in an AD mouse model.
• The therapy reduced Alzheimer's disease-related pathologies, including Aβ and tau deposits.
• Single-nucleus transcriptomic analysis confirmed cell-type-specific reversal of disease-associated gene networks.

Conclusions:

• Cell-type-directed combination therapies represent a promising strategy for multifactorial diseases like Alzheimer's disease.
• This approach supports the development of precision medicine tailored to individual patient profiles.
• The identified combination therapy warrants further investigation for clinical application in Alzheimer's disease treatment.